Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: Cocktails and chemistries

BMC Molecular Biology

Volumn 8, Issue , 2007, Pages

  Adams, Abbie M ^a   Harding, Penny L ^a   Iversen, Patrick L ^b   Coleman, Catherine ^a   Fletcher, Sue ^a   Wilton, Steve D ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b AVI BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' O METHYL ANTISENSE OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; DNA; DYSTROPHIN; MESSENGER RNA; OLIGOMER; PHOSPHOROTHIOIC ACID DERIVATIVE; UNCLASSIFIED DRUG; RNA PRECURSOR;

ARTICLE; CONTROLLED STUDY; DNA FLANKING REGION; EXON; GENE SEQUENCE; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MYOBLAST; MYOTUBE; PROTEIN MOTIF; RNA PROCESSING; RNA SPLICING; SEQUENCE ANALYSIS; CELL CULTURE; CHEMISTRY; GENETICS; METABOLISM;

ANIMALIA;

CELLS, CULTURED; DYSTROPHIN; EXONS; HUMANS; MYOBLASTS; OLIGONUCLEOTIDES, ANTISENSE; RNA PRECURSORS; TRANSFECTION;

EID: 34547683613     PISSN: None     EISSN: 14712199     Source Type: Journal    
DOI: 10.1186/1471-2199-8-57     Document Type: Article

References (39)

1. Braasch DA Jensen S Liu Y Kaur K Arar K White MA Corey DR RNA interference in mammalian cells by chemically-modified RNA Biochemistry 2003 42 7967-7975 10.1021/bi0343774 12834349
2. Amantana A Iversen PL Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers Curr Opin Pharmacol 2005 5 550-555 10.1016/j.coph.2005.07.001 16087398
3. Arora V Knapp DC Smith BL Statdfield ML Stein DA Reddy MT Weller DD Iversen PL c-Myc antisense limits rat liver regeneration and indicates role for c-Myc in regulating cytochrome P-450 3A activity J Pharmacol Exp Ther 2000 292 921-928 10688605
4. Deas TS Binduga-Gajewska I Tilgner M Ren P Stein DA Moulton HM Iversen PL Kauffman EB Kramer LD Shi PY Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication J Virol 2005 79 4599-4609 1069577 15795246 10.1128/ JVI.79.8.4599-4609.2005
5. Vickers TA Wyatt JR Burckin T Bennett CF Freier SM Fully modified 2′ MOE oligonucleotides redirect polyadenylation Nucleic Acids Res 2001 29 1293-1299 29745 11238995 10.1093/nar/29.6.1293
6. Wilton SD Fletcher S RNA splicing manipulation: Strategies to modify gene expression for a variety of therapeutic outcomes Curr Gene Ther 2005 5 467-483 10.2174/156652305774329249 16250888
7. Emery AE Muscular dystrophy into the new millennium Neuromuscul Disord 2002 12 343-349 10.1016/S0960-8966(01)00303-0 12062251
8. Wilton SD Lloyd F Carville K Fletcher S Honeyman K Agrawal S Kole R Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides Neuromuscul Disord 1999 9 330-338 10.1016/S0960-8966(99)00010-3 10407856
9. Mann CJ Honeyman K Cheng AJ Ly T Lloyd F Fletcher S Morgan JE Partridge TA Wilton SD Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse Proc Natl Acad Sci USA 2001 98 42-47 14541 11120883 10.1073/pnas.011408598
10. Bremmer-Bout M Aartsma-Rus A de Meijer EJ Kaman WE Janson AA Vossen RH van Ommen GJ den Dunnen JT van Deutekom JC Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides Mol Ther 2004 10 232-240 10.1016/j.ymthe.2004.05.031 15294170
11. McClorey G Moulton HM Iversen PL Fletcher S Wilton SD Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD Gene Ther 2006 13 1373-1381 10.1038/ sj.gt.3302800 16724091
12. Aartsma-Rus A Kaman WE Bremmer-Bout M Janson AA den Dunnen JT van Ommen GJ van Deutekom JC Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells Gene Ther 2004 11 1391-1398 10.1038/sj.gt.3302313 15229633
13. Aartsma-Rus A Janson AA Kaman WE Bremmer-Bout M den Dunnen JT Baas F van Ommen GJ van Deutekom JC Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients Hum Mol Genet 2003 12 907-914 10.1093/hmg/ddg100 12668614
14. Aartsma-Rus A De Winter CL Janson AA Kaman WE Van Ommen GJ Den Dunnen JT Van Deutekom JC Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: Indication for steric hindrance of SR protein binding sites Oligonucleotides 2005 15 284-297 10.1089/ oli.2005.15.284 16396622
15. Gebski BL Errington SJ Johnsen RD Fletcher S Wilton SD Terminal antisense oligonucleotide modifications can enhance induced exon skipping Neuromuscul Disord 2005 15 622-629 10.1016/j.nmd.2005.06.009 16084084
16. Gebski BL Mann CJ Fletcher S Wilton SD Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle Hum Mol Genet 2003 12 1801-1811 10.1093/hmg/ddg196 12874101
17. Fletcher S Honeyman K Fall AM Harding PL Johnsen RD Wilton SD Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide J Gene Med 2006 8 207-216 10.1002/jgm.838 16285002
18. Alter J Lou F Rabinowitz A Yin H Rosenfeld J Wilton SD Partridge TA Lu QL Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology Nat Med 2006 12 175-177 10.1038/nm1345 16444267
19. Wilton SD Fall AM Harding PL McClorey G Coleman C Fletcher S Antisense oligonucleotide induced exon skipping across the human dystrophin gene transcript Molecular Therapy 2007 15 7 1288-1296 10.1038/sj.mt.6300095 17285139
20. Arora V Devi GR Iversen PL Neutrally charged phosphorodiamidate morpholino antisense oligomers: Uptake, efficacy and pharmacokinetics Curr Pharm Biotechnol 2004 5 431-439 10.2174/1389201043376706 15544491
21. Devi GR Beer TM Corless CL Arora V Weller DL Iversen PL In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI- in solid tumors Clin Cancer Res 4126 11 3930-3938 10.1158/1078-0432.CCR-04-2091
22. Kipshidze N Tsapenko M Iversen P Burger D Antisense therapy for restenosis following percutaneous coronary intervention Expert Opin Biol Ther 2005 5 79-89 10.1517/14712598.5.1.79 15709911
23. Cartegni L Wang J Zhu Z Zhang MQ Krainer AR ESEfinder: A web resource to identify exonic splicing enhancers Nucleic Acids Res 2003 31 3568-3571 169022 12824367 10.1093/nar/gkg616
24. Errington SJ Mann CJ Fletcher S Wilton SD Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene J Gene Med 2003 5 518-527 10.1002/jgm.361 12797117
25. Matsuo M Duchenne/Becker muscular dystrophy: From molecular diagnosis to gene therapy Brain Dev 1996 18 167-172 10.1016/0387-7604(96)00007-1 8836495
26. Fall AM Johnsen R Honeyman K Iversen P Fletcher S Wilton SD Induction of revertant fibres in the mdx mouse using antisense oligonucleotides Genet Vaccines Ther 2006 4 3 1481566 16719929 10.1186/1479-0556-4-3
27. Gospe SM Jr Lazaro RP Lava NS Grootscholten PM Scott MO Fischbeck KH Familial X-linked myalgia and cramps: A nonprogressive myopathy associated with a deletion in the dystrophin gene Neurology 1989 39 1277-1280 2677830
28. Partridge M Vincent A Matthews P Puma J Stein D Summerton J A simple method for delivering morpholino antisense oligos into the cytoplasm of cells Antisense Nucleic Acid Drug Dev 1996 6 169-175 8915501
29. Ghosh C Iversen PL Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomers Antisense Nucleic Acid Drug Dev 2000 10 263-274 10.1089/108729000421448 10984120
30. Alonso M Stein DA Thomann E Moulton HM Leong JC Iversen P Mourich DV Inhibition of infectious haematopoietic necrosis virus in cell cultures with peptide-conjugated morpholino oligomers J Fish Dis 2005 28 399-410 10.1111/j.1365-2761.2005.00641.x 16083445
31. Moulton HM Hase MC Smith KM Iversen PL HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers Antisense Nucleic Acid Drug Dev 2003 13 31-43 10.1089/108729003764097322 12691534
32. Moulton HM Nelson MH Hatlevig SA Reddy MT Iversen PL Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides Bioconjug Chem 2004 15 290-299 10.1021/bc034221g 15025524
33. Fletcher S Honeyman K Fall AM Harding PL Johnsen R Steinhaus JP Moulton HM Iversen PL Wilton SD Morpholino oligomer mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse Molecular Therapy 2007 accepted, subject to minor revision.
34. Harding PL Fall AM Honeyman K Fletcher S Wilton SD The influence of antisense oligonucleotide length on dystrophin exon skipping Mol Ther 2006 15 157-166 10.1038/sj.mt.6300006
35. Sicinski P Geng Y Ryder-Cook AS Barnard EA Darlison MG Barnard PJ The molecular basis of muscular dystrophy in the mdx mouse: A point mutation Science 1989 244 1578-1580 10.1126/science.2662404 2662404
36. Mann CJ Honeyman K McClorey G Fletcher S Wilton SD Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy J Gene Med 2002 4 644-654 10.1002/jgm.295 12439856
37. Rando TA Blau HM Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy J Cell Biol 1994 125 1275-1287 10.1083/jcb.125.6.1275 8207057
38. Morgan JE Beauchamp JR Pagel CN Peckham M Ataliotis P Jat PS Noble MD Farmer K Partridge TA Myogenic Cell Lines Derived from Transgenic Mice Carrying a Thermolabile T Antigen: A Model System for the Derivation of Tissue-Specific and Mutation-Specific Cell Lines Developmental Biology 1994 162 486-498 10.1006/dbio.1994.1103 8150209
39. Wilton SD Lim L Dye D Laing N Bandstab: A PCR-based alternative to cloning PCR products Biotechniques 1997 22 642-645 9105612